CompletedPhase 2ACTRN12612000249853

Effect of ion channel modification on symptoms in chronic eczema

In Dermatologist or Allergist diagnosed eczema, does use of multi-transient receptor potential modifying compound (MTRPMC) formulation plus placebo compared with no MTRPMC formulation plus placebo improve PO SCORAD


Sponsor

Peter Smith

Enrollment

20 participants

Start Date

Jul 1, 2013

Study Type

Interventional

Conditions

Summary

This study aims to investigate the efficacy of naturally occurring edible compounds, that effect (block or activate) ion channels on nerves and some cells involved in inflammation, used topically to reduce the symptoms of chronic eczema. The eczema study will investigate patients with Dermatologist or Allergist diagnosed eczema who have significantly impaired quality of life and frequent need for moisturising creams and topical steroids. A randomized, controlled, crossover clinical trial will be undertaken with 2 sequential arms of treatment, 13 weeks duration each, and a 2 week washout period between each arm. One of the treatment arms will be active and one will be placebo. Patients will have a SCORAD completed at weeks 0 and 13 of each treatment arm with weekly PO-SCORAD measurements for self completion in between. Use of steroid cream, number of infected eczema episodes and quality of life measures will also be recorded. Patients will be recruited through specialist allergist and dermatology rooms.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria7

  • Dermatologist or Allergist diagnosed eczema severity moderate-severe
  • Significant impairment of quality of life
  • Need for frequent moisturising and topical steroids
  • Must have indicated a willingness to enter the study
  • Must have read and fully understood a study information form
  • Must have had the opportunity to ask any questions prior to enrolment
  • Must have signed study consent form

Exclusion Criteria5

  • Pregnant or likely to become pregnant
  • People whose primary language is other than English (LOTE)
  • People with a cognitive impairment, an intellectual disability or a mental illness
  • Children and/or young people (ie. <18 years)
  • Any history of reaction or intolerance to MTRPMC formulation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Arm 1: MTRPMC formulation (glycerine cream plus actives) Dose: Apply topically when required for itch/pain associated with eczema Arm 2: Placebo (glycerine cream) Dose: Apply topically when require

Arm 1: MTRPMC formulation (glycerine cream plus actives) Dose: Apply topically when required for itch/pain associated with eczema Arm 2: Placebo (glycerine cream) Dose: Apply topically when required for itch/pain associated with eczema Each intervention will be given for 13 weeks with a 2 week washout between each arm


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000249853